Soluble Hla Class I Antigens in Chronic Hepatitis C: A Disease-Associated Manifestan or Molecules Modulating Immunoresponsiveness?

References

• Calne R. Y., White H. J., Yoffa D. E., Maggin R. R., Binns R. M., Samuel J. R., Molina V. P. Observations of orthotopic liver transplantation in the pig. Br. Med. J. 1967; 2: 478
   PubMedGoogle Scholar
• Calne R. Y., Sells R. A., Pena J. R., Davis D. R., Millard P. R., Herbertson P. M., Binns R. M., Davies D. A. Induction of immunological tolerance by porcine liver allografts. Nature 1969; 223: 472
   PubMed Web of Science ®Google Scholar
• Zimmermann F. A., Butcher G. W., Davies H. S., Brons G., Kamada N., Turel O. Techniques for orthotopic liver transplantation in the rat and some studies of the immunological responses to fully allogeneic liver grafts. Transplant. Proc. 1979; 11: 571
   PubMedGoogle Scholar
• Van Rood J. J., Van Leeuwan A., Van Santen M. C.T. Anti HLA-A2 inhibitor in normal human sera. Nature 1970; 226: 366
   PubMed Web of Science ®Google Scholar
• Mathew J. M., Shenoy S., Phelan D., Lowell J., Howard T., Mohanakumar T. Biochemical and immunological evaluation of donor specific soluble HLA in the circulation of liver transplant recipients. Transplantation 1996; 62: 217
   PubMedGoogle Scholar
• Zavazava N., Böttcher H., Mueller-Ruchholtz W. M. Soluble MHC class I antigens (sHLA) and anti-HLA antibodies in heart and kidney allograft recipients. Tissue Antigens 1993; 42: 20
   PubMed Web of Science ®Google Scholar
• DeVito-Haynes L. D., Jankowska-Gan E., Sollinger H. W., Knechtle S. J., Burlingham W. J. Monitoring of kidney and simultaneous pancreas-kidney transplantation rejection by release of donor-specific soluble HLA class I. Hum. lmmunol. 1994; 40: 191
   PubMed Web of Science ®Google Scholar
• Puppo F., Scudeletti M., Indiveri F., Ferrone S. Serum HLA class I antigens: markers and modulators of an immune response?. Immunol. today 1995; 16: 124
   PubMedGoogle Scholar
• Emerson S., Murphy D., Cone R. Selective turnover and shedding of H-2K and H-2D antigens is controlled by the major histocompatibility complex. J. Exp. Med. 1980; 152: 783
   PubMedGoogle Scholar
• Emerson S., Cone R. Absorption of shed I-Ak and H-2Kk antigens by lymphoid cells. Transplantation 1982; 33: 36
   PubMedGoogle Scholar
• Zavazava N. Soluble HLA class I molecules: biological significance and clinical implications. Mol. Med. Today 1998; 4: 116
   PubMedGoogle Scholar
• Allison J. P., Pellegrino M. A., Ferrone S., Callahan G. N., Reisfeld R. A. Biologic and chemical characterization of HLA antigens in human serum. J. Immunol. 1977; 118: 1004
   PubMed Web of Science ®Google Scholar
• McDonald J. C., Gelder F. B., Aultman D. F., Landreneau M. D., McMillan R. W., Singh I., Sorrells D., Liou W. H. HLA in human serum: quantitation of class I by enzyme immunoassay. Transplantation 1992; 53: 445
   PubMedGoogle Scholar
• Inostroza J., Ferrada J., Navarrete C., Sorensen R. U. Soluble histocompatibility class I antigens and beta 2-microglobulin in pregnant females and cord blood samples. Hum. Immunoi. 1997; 54: 63
   PubMedGoogle Scholar
• Alvarez-Cermeno J., Echevarria J. M., Villar L. M., Lazaro I., Bootello A., Gonzalez-Porque P. Soluble class I antigens in serum and CSF of patients with varicella-zoster virus meningitis. J. Neural. Neurosurg. Psychiatry 1989; 52: 1194
   PubMedGoogle Scholar
• Ferreira A., Villar M. L., Alvarez-Cermeno J. C., Revilla Y., Garcia Rodriguez M. C., Fontan G., Gonzalez-Porque P. Quantification of soluble serum HLA class I antigens in healthy volunteers and AIDS patients. Clin. Chim. Acta 1988; 174: 207
   PubMed Web of Science ®Google Scholar
• Puppo F., Orlandini A., Ruzzenenti R., Comuzio S., Salamito A., Farinelli A., Stagnaro R., Indiveri F. HLA class I soluble antigen serum levels in HIV-positive subjects: correlation with cellular and serological parameters. Cancer Detect. Prevent 1990; 14: 321
   PubMedGoogle Scholar
• Puppo F., Brenci S., Lanza L., Bosco O., Imro M. A., Scudeletti M., Indiveri F., Ferrone S. Increased level of serum HLA class I antigens in HIV infection. Correlation with disease progression. Hum. Immunol. 1994; 40: 259
   PubMed Web of Science ®Google Scholar
• Filaci G., Contini P., Brenci S., Gazzolla P., Lanza L., Scudeletti M., Indiveri F., Mancardi G. L., Puppo F. Soluble HLA class I and class II molecule levels in serum and cerebrospinal fluid of multiple sclerosis patients. Hum. Immunol. 1997; 54: 54
   PubMed Web of Science ®Google Scholar
• Wolf R. E., Adamashvili I. M., Gelder F. B., Hall V. C., Fraser P. A., McDonald J. C. Soluble HLA-I in rheumatic diseases. Hum. Immunol. 1998; 59: 644
   PubMedGoogle Scholar
• Puppo F., Brenci S., Montinaro E., Lanza L., Contini P., Scudeletti M., Indiveri F. Inhibition of alloreactive cytotoxic T cell activity by HIV-positive sera: potential role of circulating soluble HLA class I molecules. AIDS Res. Hum. Retrovir. 1994; 10: 1061
   PubMed Web of Science ®Google Scholar
• Ghio M., Contini P., Mazzei C., Brenci S., Barberis G., Filaci G., Indiveri F., Puppo F. Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. Blood 1999; 93: 1770
   PubMed Web of Science ®Google Scholar
• Fiore G., Angarano I., Caccetta L., Serrone M., Jirillo E., Schiraldi O., Antonaci S. In-situ immunophenotyping study of hepatic-infiltrating cytotoxic cells in chronic active hepatitis C. Eur. J. Gastroenterol. Hepatol. 1997; 9: 491
   PubMed Web of Science ®Google Scholar
• Fiore G., Piazzolla G., Angarano I., Galetta V., Caccetta L, Jirillo E., Schiraldi O., Antonaci S. Intrahepatic cytotoxic cell infiltrates in chronic hepatitis B and C: a comparative immunohistochemical study. Med. Sci. Res. 1997; 25: 755
   Google Scholar
• Khakoo S. I., Soni P. M., Savage K., Brown D., Dhillon A. P., Poulter L. W., Dusheiko G. M. Lymphocyte and macrophage phenotypes in chronic hepatitis C infection. Am. J. Pathol. 1997; 150: 963
   PubMed Web of Science ®Google Scholar
• Fiore G., Galetta V., Piazzolla G., Angarano I., Jirillo E., Schiraldi O., Antonaci S. CD45RA and CD45RO isoform expression on intrahepatic T-lymphocytes in chronic hepatitis C. Microbios 1997; 92: 73
   PubMedGoogle Scholar
• Onji M., Kikuchi T., Kumon I., Masumoto T., Nadano S., Kajno K., Horiike N., Ohta Y. Intrahepatic lymphocyte subpopulations and HLA class I antigen expression by hepatocytes in chronic hepatitis C. Hepatogastroenterology 1992; 39: 340
   PubMed Web of Science ®Google Scholar
• Volpes R., Van Der Oord J. J., Desmet V. J. Memory T cells represent the predominant lymphocyte subset in acute and chronic liver inflammation. Hepatology 1991; 13: 826
   PubMed Web of Science ®Google Scholar
• Mosnier J. F., Scoazec J. Y., Marcellin P., Degott C., Benhamou J. P., Feldmann G. Expression of cytokine-dependent immune adhesion molecules by hepatocytes and bile duct cells in chronic hepatitis C. Gastroenterology 1994; 107: 1457
   PubMed Web of Science ®Google Scholar
• Mochizuki K., Hayashi N., Katayama K., Hiramitsu N., Kanto T., Mita E., Tatsumi T., Kuzushita N., Kasahara A., Fusamoto H., Yokochi T., Kamada T. B7/BB-1 expression and hepatitis activity in liver tissues of patients with chronic hepatitis C. Hepatology 1997; 25: 713
   PubMed Web of Science ®Google Scholar
• Hiramatsu N., Hayashi N., Katayama K., Mochizuchi K., Kawanishi Y., Kasahara A., Fusamoto H., Kamada T. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 1994; 19: 1354
   PubMed Web of Science ®Google Scholar
• Antonaci S., Schiraldi O. Costimulatory molecules and cytotoxic T cells in chronic hepatitis C: defence mechanisms devoted to host integrity or harmful events favouring liver injury progression? A review. Immunopharmacol. Immunotoxicol. 1998; 20: 455
   PubMed Web of Science ®Google Scholar
• Fiore G., Piazzolla G., Galetta V., Caccetta L., Schiraldi O., Antonaci S. Liver tissue expression of CD80 and CD95 antigens in chronic hepatitis C: relationship with biological and histological disease activity. Microbios 1999; 97: 29
   PubMedGoogle Scholar
• Liaw Y. F., Lee C. S., Tsai S. L, Liaw B. W., Chen T. C., Sheen I. S., Chu C. M. T cell-mediated autologous hepatocytotoxicity in patients with chronic hepatitis C virus infection. Hepatology 1995; 22: 1368
   PubMedGoogle Scholar
• Piazzolla G., Giannelli L., Antonelli G., Tortorella C., Jirillo E., Schiraldi O., Antonaci S. Effects of interferon-α treatment on neutrophil oxidative metabolism, lymphocyte proliferation and monocyte HLA class I antigen expression in patients with chronic hepatitis C. Immunopharmacol. Immunotoxicol. 1996; 18: 529
   PubMed Web of Science ®Google Scholar
• Kuzushita N., Hayashi N., Moribe T., Katayama K., Kanto T., Nakatani S., Kaneshige T., Tatsumi T., Ito A., Mochizuki K., Sasaki Y., Kasahara A., Hori M. Influence of HLA haplotypes on the clinical course of individuals infected with hepatitis C virus. Hepatology 1998; 27: 240
   PubMedGoogle Scholar
• Olcese L, Lang P., Vely F., Cambiaggi A., Marguet D., Blery M., Hippen K. L., Biassoni R., Moretta A., Moretta L, Cambier J. C., Vivier E. Human and mouse killer-cell inhibitory receptors recruit PTP1C and PTP1D protein tyrosine phosphatases. J. Immunol. 1996; 156: 4531
   PubMed Web of Science ®Google Scholar
• Large M. K., Kittlesen D. J., Hahn Y. S. Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. J. Immunol. 1999; 162: 931
   PubMed Web of Science ®Google Scholar
• Tsai S. L., Chen Y. M., Chen M. H., Huang C. Y., Sheen I. S., Yeh C. T., Huang J. H., Kuo G. C., Liaw Y. F. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity. Gastroenterology 1998; 115: 954
   PubMedGoogle Scholar
• Puppo F., Picciotto A., Brenci S., Varagona G., Scudeletti M., Ghio M., Balestra V., Celle G., Indiveri F. Behaviour of soluble HLA class I antigens in patients with chronic hepatitis C during interferon therapy: an early predictor marker of response?. J. Clin. Immunol. 1995; 15: 179
   PubMed Web of Science ®Google Scholar
• Hagihara M., Shimura T., Takebe K., Munkhbat B., Yamamoto K., Hosoi K., Kagawa T., Watanabe N., Matsuzaki S., Tsuji K. The changes of serum soluble HLA-class I and CD8 concentrations during interferon treatment of chronic hepatitis C patients. Int. Hepatol. Commun. 1997; 6: 316
   Google Scholar
• Freni M. A., Ajello A., Spadaro A., Fava A., Calapristi I., Marafioti T., Alessi N., Resta M. L., Ferrau O. Class I HLA antigens hepatic display and Beta-2-microglobulin serum values in chronic hepatitis C: effect of treatment with recombinant alpha interferon. Hepatogastroenterology 1997; 44: 1295
   PubMedGoogle Scholar
• Singer D. S., Maguire J. E. Regulation of the expression of class I MHC genes. Crit. Rev. Immunol. 1990; 10: 235
   PubMedGoogle Scholar
• Hagihara M., Shimura T., Takebe K., Munkhbat B., Hosoi K., Kagawa T., Watanabe N., Matsuzaki S., Yamamoto K., Sato K., Tsuji K. Serum concentrations of soluble HLA-class I and CD8 forms in patients with viral hepatic disorders. J. Gastroenterol. 1997; 32: 338
   PubMed Web of Science ®Google Scholar
• Piazzolla G., Tortorella C., Fiore G., Serrone M., Caccetta L., Jirillo E., Schiraldi O., Antonaci S. Immunoresponsiveness in chronic hepatitis C patients: correlation between tissue and serum findings. Immunopharmacol. Immunotoxicol. 1998; 20: 337
   PubMed Web of Science ®Google Scholar
• Quiroga J. A., Martin J., Pardo M., Carreno V. Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C, and their relation to therapeutic response to interferon-α. Dig. Dis. Sci. 1994; 39: 2485
   PubMed Web of Science ®Google Scholar
• Kaplanski G., Farnarier C., Payan M. J., Bongrand P., Durand J. M. Increased levels of soluble adhesion molecules in the serum of patients with hepatitis C. Correlation with cytokine concentrations and liver inflammation and fibrosis. Dig. Dis. Sci. 1997; 42: 2277
   PubMedGoogle Scholar
• Zavazava N., Kronke M. Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes. Nat. Med. 1996; 2: 1005
   PubMed Web of Science ®Google Scholar
• Nagata S., Golstein P. The Fas death factor. Science 1995; 267: 1449
   PubMed Web of Science ®Google Scholar
• Tanaka M., Suda T., Takahashi T., Nagata S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J. 1995; 14: 1129
   PubMed Web of Science ®Google Scholar